Advertisement

Der Gastroenterologe

, Volume 14, Issue 2, pp 131–148 | Cite as

Duktales Adenokarzinom des Pankreas

  • E. GallmeierEmail author
  • T. M. Gress
CME
  • 261 Downloads

Zusammenfassung

Das duktale Adenokarzinom ist die häufigste maligne Raumforderung des Pankreas. Trotz großer Forschungsanstrengungen und gradueller Verbesserungen der Diagnostik und Therapie weist es immer noch eine sehr ungünstige Prognose auf. Dieser CME-Fortbildungsbeitrag liefert unter Berücksichtigung der aktuellen deutschen, europäischen und US-amerikanischen Leitlinien einen allgemeinen Überblick zu dieser Erkrankung. Zudem werden ausgewählte aktuelle Aspekte der Epidemiologie, Pathogenese und Genetik sowie Grundprinzipien der Diagnostik und Therapie einschließlich potenzieller zukünftiger Therapieoptionen erörtert.

Schlüsselwörter

Pankreaskarzinom Pathogenese Diagnose Therapie Genetik 

Pancreatic ductal adenocarcinoma

Abstract

Pancreatic ductal adenocarcinoma represents the most common malignant tumor of the pancreas. Despite substantial research efforts and gradual diagnostic and therapeutic improvements, its prognosis remains dismal. In accordance with the current German, European, and US guidelines, this CME-article provides a comprehensive review of the disease. In addition, selected up-to-date aspects of epidemiology, etiopathology, genetics, and basic principles of diagnostics and therapy including potential future therapeutic options are discussed.

Keywords

Pancreatic cancer Etiopathology Diagnosis Therapy Genetics 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

E. Gallmeier erhielt Honorare von Baxalta/Shire und Celgene, T.M. Gress von Novartis, Falk Foundation und Ipsen Pharma.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Fitzgerald TL, Hickner ZJ, Schmitz M et al (2008) Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 37:134–138PubMedGoogle Scholar
  2. 2.
    Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system, 4. Aufl. World Health Organization (WHO), International Agency for Research on Cancer (IARC), LyonGoogle Scholar
  3. 3.
    Malvezzi M, Carioli G, Bertuccio P et al (2018) European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol.  https://doi.org/10.1093/annonc/mdy033 CrossRefPubMedGoogle Scholar
  4. 4.
    Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921PubMedPubMedCentralGoogle Scholar
  5. 5.
    Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67:7–30Google Scholar
  6. 6.
    Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024PubMedGoogle Scholar
  7. 7.
    Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703Google Scholar
  8. 8.
    Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825PubMedGoogle Scholar
  9. 9.
    Oettle H, Neuhaus P, Hochhaus A et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473–1481PubMedGoogle Scholar
  10. 10.
    Bailey P, Chang DK, Nones K et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47–52PubMedGoogle Scholar
  11. 11.
    Cancer Genome Atlas Research Network Electronic address aadhe, cancer genome atlas research N (2017) integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32:185–203.e13Google Scholar
  12. 12.
    Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806PubMedPubMedCentralGoogle Scholar
  13. 13.
    Waddell N, Pajic M, Patch AM et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–501PubMedPubMedCentralGoogle Scholar
  14. 14.
    Witkiewicz AK, McMillan EA, Balaji U et al (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6:6744PubMedPubMedCentralGoogle Scholar
  15. 15.
    Roberts NJ, Norris AL, Petersen GM et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6:166–175PubMedGoogle Scholar
  16. 16.
    Petersen GM (2016) Familial pancreatic cancer. Semin Oncol 43:548–553PubMedPubMedCentralGoogle Scholar
  17. 17.
    Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617PubMedGoogle Scholar
  18. 18.
    Bartsch DK, Slater EP, Carrato A et al (2016) Refinement of screening for familial pancreatic cancer. Gut 65:1314–1321PubMedGoogle Scholar
  19. 19.
    Korc M, Jeon CY, Edderkaoui M et al (2017) Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 31:529–536PubMedPubMedCentralGoogle Scholar
  20. 20.
    Ducreux M, Cuhna AS, Caramella C et al (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56–v68PubMedGoogle Scholar
  21. 21.
    Maisonneuve P, Lowenfels AB (2015) Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol 44:186–198PubMedGoogle Scholar
  22. 22.
    Hruban RH, Goggins M, Parsons J et al (2000) Progression model for pancreatic cancer. Clin Cancer Res 6:2969–2972PubMedGoogle Scholar
  23. 23.
    Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532Google Scholar
  24. 24.
    Yachida S, Iacobuzio-Donahue CA (2013) Evolution and dynamics of pancreatic cancer progression. Oncogene 32:5253–5260PubMedGoogle Scholar
  25. 25.
    Basturk O, Hong SM, Wood LD et al (2015) A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39:1730–1741PubMedPubMedCentralGoogle Scholar
  26. 26.
    Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons, Chichester, HobokenGoogle Scholar
  27. 27.
    Porta M, Fabregat X, Malats N et al (2005) Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7:189–197PubMedGoogle Scholar
  28. 28.
    Mujica VR, Barkin JS, Go VL (2000) Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants. Pancreas 21:329–332PubMedGoogle Scholar
  29. 29.
    Chari ST, Leibson CL, Rabe KG et al (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129:504–511PubMedPubMedCentralGoogle Scholar
  30. 30.
    Seufferlein T, Porzner M, Becker T et al (2013) S3-guideline exocrine pancreatic cancer. Z Gastroenterol 51:1395–1440PubMedGoogle Scholar
  31. 31.
    Duffy MJ, Sturgeon C, Lamerz R et al (2010) Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 21:441–447PubMedGoogle Scholar
  32. 32.
    Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3:105–119PubMedPubMedCentralGoogle Scholar
  33. 33.
    Kim JE, Lee KT, Lee JK et al (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:182–186PubMedGoogle Scholar
  34. 34.
    Al-Hawary MM, Francis IR, Chari ST et al (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology 146:291–304.e1PubMedGoogle Scholar
  35. 35.
    Bipat S, Phoa SS, van Delden OM et al (2005) Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 29:438–445PubMedGoogle Scholar
  36. 36.
    Nawaz H, Fan CY, Kloke J et al (2013) Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP 14:484–497PubMedPubMedCentralGoogle Scholar
  37. 37.
    Okasha HH, Naga MI, Esmat S et al (2013) Endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasound-guided fine needle aspiration in diagnosis of focal pancreatic masses. Endosc Ultrasound 2:190–193PubMedPubMedCentralGoogle Scholar
  38. 38.
    Micames C, Jowell PS, White R et al (2003) Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 58:690–695PubMedGoogle Scholar
  39. 39.
    Tempero MA, Malafa MP, Al-Hawary M et al (2017) Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:1028–1061PubMedGoogle Scholar
  40. 40.
    Barreto SG, Windsor JA (2016) Justifying vein resection with pancreatoduodenectomy. Lancet Oncol 17:e118–e124PubMedGoogle Scholar
  41. 41.
    Evans DB, George B, Tsai S (2015) Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of Multimodality therapy. Ann Surg Oncol 22:3409–3413PubMedGoogle Scholar
  42. 42.
    Lutz MP, Zalcberg JR, Ducreux M et al (2017) 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 79:41–49PubMedGoogle Scholar
  43. 43.
    Finks JF, Osborne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128–2137PubMedPubMedCentralGoogle Scholar
  44. 44.
    Reames BN, Ghaferi AA, Birkmeyer JD et al (2014) Hospital volume and operative mortality in the modern era. Ann Surg 260:244–251PubMedPubMedCentralGoogle Scholar
  45. 45.
    Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585PubMedGoogle Scholar
  46. 46.
    Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081PubMedGoogle Scholar
  47. 47.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277PubMedGoogle Scholar
  48. 48.
    Nagrial AM, Chang DK, Nguyen NQ et al (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer 110:313–319PubMedGoogle Scholar
  49. 49.
    Conroy T et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406PubMedGoogle Scholar
  50. 50.
    Valle JW, Palmer D, Jackson R et al (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504–512PubMedGoogle Scholar
  51. 51.
    Tol JA, Gouma DJ, Bassi C et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156:591–600PubMedGoogle Scholar
  52. 52.
    Hartwig W, Hackert T, Hinz U et al (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254:311–319PubMedGoogle Scholar
  53. 53.
    Kim KS, Kwon J, Kim K et al (2017) Impact of resection margin distance on survival of pancreatic cancer: a systematic review and meta-analysis. Cancer Res Treat 49:824–833PubMedGoogle Scholar
  54. 54.
    van der Gaag NA, Rauws EA, van Eijck CH et al (2010) Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362:129–137PubMedGoogle Scholar
  55. 55.
    Tol JA, van Hooft JE, Timmer R et al (2016) Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut 65:1981–1987PubMedGoogle Scholar
  56. 56.
    Ettrich TJ, Schulte LA, Eitel N et al (2017) Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent—a multicenter survey in Germany and review of the literature. Z Gastroenterol 55:657–666PubMedGoogle Scholar
  57. 57.
    Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Plos Med 7:e1000267PubMedPubMedCentralGoogle Scholar
  58. 58.
    Balaban EP, Mangu PB, Khorana AA et al (2016) Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:2654–2668PubMedGoogle Scholar
  59. 59.
    Rombouts SJ, Walma MS, Vogel JA et al (2016) Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol 23:4352–4360PubMedPubMedCentralGoogle Scholar
  60. 60.
    Wagner M, Antunes C, Pietrasz D et al (2017) CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 27:3104–3116PubMedGoogle Scholar
  61. 61.
    Hurt CN, Mukherjee S, Bridgewater J et al (2015) Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 93:810–818PubMedPubMedCentralGoogle Scholar
  62. 62.
    Mukherjee S, Hurt CN, Bridgewater J et al (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 14:317–326PubMedPubMedCentralGoogle Scholar
  63. 63.
    Hammel P, Huguet F, van Laethem JL et al (2016) Effect of cemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853PubMedGoogle Scholar
  64. 64.
    Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  65. 65.
    Li D, Capanu M, Yu KH et al (2015) Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clin Colorectal Cancer 14:269–276e1PubMedPubMedCentralGoogle Scholar
  66. 66.
    Hackert T, Niesen W, Hinz U et al (2017) Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 43:358–363PubMedGoogle Scholar
  67. 67.
    Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMedGoogle Scholar
  68. 68.
    Wang-Gillam A, Li CP, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557PubMedGoogle Scholar
  69. 69.
    Haas M, Siveke JT, Schenk M et al (2018) Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: a prospective phase II study of the ‚Arbeitsgemeinschaft Internistische Onkologie‘. Eur J Cancer 94:95–103PubMedGoogle Scholar
  70. 70.
    Sinn M, Bahra M, Liersch T et al (2017) CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 35:3330–3337PubMedGoogle Scholar
  71. 71.
    Vogel A, Kullmann F, Kunzmann V et al (2015) Patients with advanced pancreatic cancer and Hyperbilirubinaemia: review and German expert opinion on treatment with nab-Paclitaxel plus Gemcitabine. Oncol Res Treat 38:596–603PubMedGoogle Scholar
  72. 72.
    Rahma OE, Duffy A, Liewehr DJ et al (2013) Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 24:1972–1979PubMedPubMedCentralGoogle Scholar
  73. 73.
    Portal A, Pernot S, Tougeron D et al (2015) Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 113:989–995PubMedPubMedCentralGoogle Scholar
  74. 74.
    Oettle H, Riess H, Stieler JM et al (2014) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32:2423–2429PubMedGoogle Scholar
  75. 75.
    Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5‑fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676–1681PubMedGoogle Scholar
  76. 76.
    Gill S, Ko YJ, Cripps C et al (2016) PANCREOX: a randomized phase III study of fluorouracil/Leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received Gemcitabine-based chemotherapy. J Clin Oncol 34:3914–3920PubMedGoogle Scholar
  77. 77.
    Hartung TJ, Brahler E, Faller H et al (2017) The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer 72:46–53PubMedGoogle Scholar
  78. 78.
    O’Donnell E (2013) The distress thermometer: a rapid and effective tool for the oncology social worker. Int J Health Care Qual Assur 26:353–359PubMedGoogle Scholar
  79. 79.
    Gotze H, Brahler E, Gansera L et al (2018) Anxiety, depression and quality of life in family caregivers of palliative cancer patients during home care and after the patient’s death. Eur J Cancer Care (engl) 27:e12606Google Scholar
  80. 80.
    Ter Veer E, van Rijssen LB, Besselink MG et al (2018) Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 19:e151–e160PubMedGoogle Scholar
  81. 81.
    Wolff RA (2018) Adjuvant or neoadjuvant therapy in the treatment in pancreatic malignancies: where are we? Surg Clin North Am 98:95–111PubMedGoogle Scholar
  82. 82.
    Mokdad AA, Minter RM, Zhu H et al (2017) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35:515–522PubMedGoogle Scholar
  83. 83.
    Krantz BA, O’Reilly EM (2017) Biomarker based therapy in pancreatic ductal Adenocarcinoma: an emerging reality? Clin Cancer Res.  https://doi.org/10.1158/1078-0432.CCR-16-3169 CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Jameson GS, Borazanci EH, Babiker HM et al (2017) A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer. J Clin Oncol 35:341–341Google Scholar
  85. 85.
    Jameson GS, Borazanci EH, Poplin E et al (2015) Abstract LB-003: High complete and partial response rate in a phase Ib pilot trial with cisplatin plus albumin-bound paclitaxel and gemcitabine in patients with advanced pancreatic cancer. Cancer Res 75:LB-3–LB-3Google Scholar
  86. 86.
    Teo MY, O’Reilly EM (2016) Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 7:738–749PubMedPubMedCentralGoogle Scholar
  87. 87.
    Lemery S, Keegan P, Pazdur R (2017) First FDA approval agnostic of cancer site—when a biomarker defines the indication. N Engl J Med 377:1409–1412PubMedGoogle Scholar
  88. 88.
    Hu ZI, Shia J, Stadler ZK et al (2018) Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 24:1326–1336PubMedPubMedCentralGoogle Scholar
  89. 89.
    Le DT, Durham JN, Smith KN et al (2017) Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science.  https://doi.org/10.1126/science.aan6733 CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Hingorani SR, Zheng L, Bullock AJ et al (2018) HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol 36:359–366PubMedGoogle Scholar
  91. 91.
    Ramanathan RK, McDonough S, Philip PA et al (2018) A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). J Clin Oncol 36(suppl 4S):abstr 208Google Scholar
  92. 92.
    Lowery MA, Jordan EJ, Basturk O et al (2017) Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res 23:6094–6100PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Innere Medizin, Gastroenterologie, Infektiologie, Endokrinologie und StoffwechselUniversitätsklinikum Giessen und Marburg GmbHMarburgDeutschland

Personalised recommendations